The American pharmaceutical company Pfizer has filed a request with the US Food and Drug Administration (FDA) for permission to use its experimental drug for the coronavirus COVID-19. This is stated in the press release of the company..

“Pfizer today announced that it is seeking emergency approval for its experimental oral antiviral drug PAXLOVID to treat COVID-19 — in mild to moderate disease — in patients at increased risk of hospitalization or death,” the press said..

If approved, PAXLOVID will be the first pill to treat COVID-19. The company insists that the drug helps to avoid the severe course of COVID-19, which leads to hospitalization and death.

The document says that the medicine will be able to be prescribed both to patients undergoing treatment at home and to patients at risk when the first signs of coronavirus infection appear..

According to Pfizer, the company is seeking approval for its coronavirus drug based on positive results from preliminary analyzes of clinical trials in which subjects aged 18 and over with a confirmed diagnosis of COVID-19 who were at high risk of progressive and severe illness.. The study showed that the drug can reduce the risk of hospitalization or death by 89%.

“With more than 5 million deaths and countless lives affected globally by this devastating disease, there is an urgent need for treatment options that will save lives. PAXLOVID is highly effective in recent clinical trials and has potential, if approved, will save lives and prevent hospitalizations. "

[see_also].

Pfizer Russia Tests New Coronavirus Drug: What You Need to Know.

[/ see_also].

Earlier it was reported that Pfizer signed an agreement with the Medicines Patent Pool, which will allow companies around the world to produce their experimental drug for the coronavirus COVID-19.. The Medicines Patent Pool is a United Nations-backed organization that promotes the development of medicines for low- and middle-income countries.

Agreement will facilitate additional production and distribution of investigational drug while Pfizer awaits regulatory approval. Qualified drug manufacturers around the world will be able to supply 95 countries with the new drug.